Bronchoalveolar lavage
HY Reynolds - American Review of Respiratory Disease, 1987 - atsjournals.org
Background Optimal design of the rigid bronchoscope was achieved by Dr. Chevalier
Jackson of Philadelphia in 1904 when he devised a light for the distal end of the …
Jackson of Philadelphia in 1904 when he devised a light for the distal end of the …
Current concepts of the pathogenesis of sarcoidosis
PD Thomas, GW Hunninghake - American Review of Respiratory …, 1987 - atsjournals.org
Current Concepts of the Pathogenesis of Sarcoidosis Page 1 Current Concepts of the
Pathogenesis of Sarcoidosis1 ,2 PD THOMAS and GW HUNNINGHAKE Contents …
Pathogenesis of Sarcoidosis1 ,2 PD THOMAS and GW HUNNINGHAKE Contents …
Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis
B White, WC Moore, FM Wigley, HQ **ao… - Annals of internal …, 2000 - acpjournals.org
Background: Lung inflammation (alveolitis) may cause lung fibrosis in scleroderma.
Objective: To determine whether cyclophosphamide treatment is associated with retention of …
Objective: To determine whether cyclophosphamide treatment is associated with retention of …
Structural Features of Interstitial Lung Disease
NK Harrison, AR Myers, B Corrin, G Soosay… - Am Rev Respir …, 1991 - atsjournals.org
Most studies of lung histology in systemic sclerosis have been based on autopsy specimens
and consequently emphasize end-stage fibrotic disease. Although occasional pathologic …
and consequently emphasize end-stage fibrotic disease. Although occasional pathologic …
Augmented production of chemokines (monocyte chemotactic protein‐1 (MCP‐1), macrophage inflammatory protein‐1α (MIP‐1α) and MIP‐1β) in patients with …
HASEGAWA, SATO, TAKEHARA - Clinical & Experimental …, 1999 - Wiley Online Library
To determine the role of chemokines in the pathogenesis of systemic sclerosis (SSc), we
examined serum levels, spontaneous production by peripheral blood mononuclear cells …
examined serum levels, spontaneous production by peripheral blood mononuclear cells …
Evaluation and management of scleroderma lung disease using bronchoalveolar lavage
RM Silver, KS Miller, MB Kinsella, EA Smith… - The American journal of …, 1990 - Elsevier
Abstract purpose: Bronchoalveolar lavage (BAL) was performed in 43 nonsmoking patients
with scleroderma (systemic sclerosis) to determine the frequency of alveolitis, the status of …
with scleroderma (systemic sclerosis) to determine the frequency of alveolitis, the status of …
Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study
VD Steen, JK Lanz Jr, C Conte… - … : Official Journal of …, 1994 - Wiley Online Library
Objective. This retrospective observational study attempted to determine whether any of the
therapies used in the management of systemic sclerosis (SSc) patients held potential benefit …
therapies used in the management of systemic sclerosis (SSc) patients held potential benefit …
Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.
I Pakas, JPA Ioannidis, K Malagari… - The Journal of …, 2002 - jrheum.org
OBJECTIVE: To evaluate the safety and efficacy of monthly intravenous pulses of
cyclophosphamide (CP) in combination with low or high doses of prednisolone in patients …
cyclophosphamide (CP) in combination with low or high doses of prednisolone in patients …
Butyrate improves skin/lung fibrosis and intestinal dysbiosis in bleomycin-induced mouse models
HJ Park, OY Jeong, SH Chun, YH Cheon… - International journal of …, 2021 - mdpi.com
Systemic sclerosis (SSc) is an autoimmune disorder characterized by fibrosis of the skin and
internal organs. Despite several studies on SSc treatments, effective treatments for SSc are …
internal organs. Despite several studies on SSc treatments, effective treatments for SSc are …
Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases
A Schnabel, M Reuter, WL Gross - Arthritis & Rheumatism, 1998 - Wiley Online Library
Objective Substantial toxicity limits the use of daily oral cyclophosphamide (CYC) for the
treatment of interstitial lung disease (ILD) due to collagen vascular diseases. We examined …
treatment of interstitial lung disease (ILD) due to collagen vascular diseases. We examined …